Serum extracellular vesicle protein levels are associated with acute coronary syndrome

Abstract

Aims:

Biomarkers are essential in the early detection of acute coronary syndromes (ACS). Serum extracellular vesicles are small vesicles in the plasma containing protein and RNA and have been shown to be involved in ACS-related processes like apoptosis and coagulation. Therefore, we hypothesized that serum extracellular vesicle protein levels are associated with ACS.

Methods and results:

Three serum extracellular vesicle proteins potentially associated with ACS were identified with differential Q-proteomics and were evaluated in 471 frozen serum samples of ACS-suspected patients presenting to the emergency department (30% of whom had an ACS). Protein levels were measured after vesicle isolation using ExoQuick. Mean serum extracellular vesicle concentration of the different proteins was compared between ACS and non-ACS patients. Selected proteins were tested in a univariate logistic regression model, as well as in a multivariate model to adjust for cardiovascular risk factors. A separate analysis was performed in men and women. In the multivariate logistic regression analysis, polygenic immunoglobulin receptor, (pIgR; OR 1.630, p=0.026), cystatin C (OR 1.641, p=0.021), and complement factor C5a (C5a, OR 1.495, p=0.025) were significantly associated with ACS, while total vesicle protein concentration was borderline significant. The association of the individual proteins with ACS was markedly stronger in men.

Conclusions:

These data show that serum extracellular vesicle pIgR, cystatin C, and C5a concentrations are independently associated with ACS and that there are pronounced gender differences. These observations should be validated in a large, prospective study to assess the potential role of vesicle content in the evaluation of patients suspected of having an ACS.

Keywords

ACS acute coronary syndrome biomarker extracellular vesicle protein

Get full access to this article

View all access options for this article.

References

World Health Organization. Cardiovascular diseases (CVDs). Fact sheet no. 317. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html (Published September 2011, consulted May 2012).

Hamm

Bassand

Agewall

. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.

Anderson

Adams

Antman

. ACC/AHA 2007 Guidelines for the management of patients with un-stable angina/non-ST-elevation myocardial infarction – executive summary. J Am Coll Cardiol 2007; 50: 652–726.

O’Connor

Bossaert

Arntz

. Acute Coronary Syndrome Chapter Collaborators. Part 9: acute coronary syndromes: 2010 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation 2010; 122: S422–S465.

Reichlin

Hochholzer

Bassetti

. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361: 858–867.

Sanchis

Bodí

Núñez

. New risk score for patients with acute chest pain, non-ST-segment deviation, and normal troponin concentrations. J Am Coll Cardiol 2005; 46: 443–449.

Pap

Pállinger

Pásztói

. Highlights of a new type of intercellular communication: microvesicle-based information transfer. Inflamm Res 2009; 58: 1–8.

Simons

Raposo

. Exosomes – vesicular carriers for intercellular communication. Curr Opin Cell Biol 2009; 21: 575–581.

Camussi

Deregibus

Bruno

. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2010; 78: 838–848.

10.

Mause

Weber

. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010; 107: 1047–1057.

11.

Morel

Pereira

Averous

. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. Atherosclerosis 2009; 204: 636–641.

12.

Owens

Mackman

. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108: 1284–1297.

13.

Shantsila

Kamphuisen

Lip

GYH

. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost 2010; 8: 2358–2368.

14.

Leroyer

Tedgui

Boulanger

. Role of microparticles in atherothrombosis. J Intern Medicine 2008; 263: 528–537.

15.

Morel

Jesel

. Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol 2011; 33: 469–486.

16.

Tushuizen

Diamant

Sturk

. Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe? Arterioscl Thromb Vasc Biol 2010; 31: 4–9.

17.

Peterson

Sander

Kaul

. Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles. Proteomics 2008; 8: 2430–2446.

18.

Simak

Holada

Vostal

. Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin. BMC Cell Biol 2002; 3: 11–20.

19.

Antoniak

Boltzen

Eisenreich

. Regulation of cardiomyocyte full-length tissue factor expression and microparticle release under inflammatory conditions in vitro. J Thromb Haemost 2009; 7: 871–878.

20.

Dignat-George

Boulanger

. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2010; 31: 27–33.

21.

Piccin

Murphy

Smith

. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007; 21: 157–171.

22.

Combes

Simon

A-C

Grau

G-E

. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93–102.

23.

Wolf

. The nature and significance of platelet products in human plasma. Brit J Haematol 1967; 13: 269–288.

24.

Mesri

Altieri

. Endothelial cell activation by leukocyte microparticles. J Immunol 1998; 161: 4382–4387.

25.

Oerlemans

Mosterd

Dekker

. Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Mol Med 2012; 4: 1176–1185.

26.

Wines

Hogarth

. IgA receptors in health and disease. Tissue Antigens 2006; 68: 103–114.

27.

Ohlmeier

Mazur

Linja-aho

. Sputum proteomics identifies elevated PIGR levels in smokers and mild- to-moderate COPD. J Proteome Res 2012; 11: 599–608.

28.

Asano

Komiyama

. Polymeric immunoglobulin receptor. J Oral Sci 2011; 52: 147–156.

29.

Dharnidharka

Kwon

Stevens

. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221–226.

30.

Koc

Batur

Karaarslan

. Clinical utility of serum cystatin C in predicting coronary artery disease. Cardiol J 2010; 17: 374–380.

31.

Kiyosue

Hirata

Ando

. Plasma cystatin C concentration reflects the severity of coronary artery disease in patients without chronic kidney disease. Circ J 2010; 74: 2441–2447.

32.

Windhausen

Hirsch

Fischer

.; for the Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem 2009; 55: 1118–1125.

33.

Ristiniemi

Lund

Tertti

. Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome. Clin Biochem 2012: 1–6.

34.

Silva

Cortez-Dias

Jorge

. Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction. Am J Cardiol 2012; 109: 1431–1438.

35.

Jernberg

Lindahl

James

. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004; 110: 2342–2348.

36.

Toft

Solbu

Kronborg

. Cystatin C as risk factor for cardiovascular events and all-cause mortality in the general population. The Tromso Study. Nephrol Dial Transplant 2012; 27: 2780–2787.

37.

Shlipak

Sarnak

Katz

. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049–2060.

38.

Vakeva

Agah

Rollins

. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Circulation 1998; 97: 2259–2267.

39.

Frangogiannis

Smith

Entman

. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31–47.

40.

Timmers

Pasterkamp

De Hoog

. The innate immune response in reperfused myocardium. Cardiovasc Res 2012; 94: 276–283.

41.

Kostner

Fahti

Case

. Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease. Clin Chim Acta 2006; 365: 129–134.

42.

Speidl

Exner

Amighi

. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005; 26: 2294–2299.

43.

Shaw

Bugiardini

Merz

CNB

. Women and ischemic heart disease. J Am Coll Cardiol 2009; 54: 1561–1575.

44.

Shaw

Bairey Merz

Pepine

. Insights from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) StudyPart I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006; 47: S4–S20.

45.

Merz

CNB

Shaw

Reis

. Insights from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) StudyPart II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 2006; 47: S21–S29.

46.

Gehrie

Reynolds

Chen

. Characterization and outcomes of women and men with non–ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. Am Heart J 2009; 158: 688–694.

47.

VanWijk

VanBavel

Sturk

. Microparticles in cardiovascular diseases. Cardiovasc Res 2003; 59: 277–287.

48.

Bernal-Mizrachi

Jimenez

. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003; 145: 962–970.

49.

Mallat

Benamer

Hugel

. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841–843.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.46 MB